Unique ID issued by UMIN | UMIN000014570 |
---|---|
Receipt number | R000016947 |
Scientific Title | Comparison of usefulness between denosumab and alendronate after teriparatide therapy in patients with glucocorticoid-induced osteoporosis (GIOP) |
Date of disclosure of the study information | 2014/07/16 |
Last modified on | 2018/08/09 14:23:47 |
Comparison of usefulness between denosumab and alendronate after teriparatide therapy in patients with glucocorticoid-induced osteoporosis (GIOP)
Denosumab or alendronate after teriparatide in GIOP patients
Comparison of usefulness between denosumab and alendronate after teriparatide therapy in patients with glucocorticoid-induced osteoporosis (GIOP)
Denosumab or alendronate after teriparatide in GIOP patients
Japan |
glucocorticoid-induced osteoporosis (GIOP)
Medicine in general | Clinical immunology | Geriatrics |
Others
NO
Comparison of usefulness between denosumab and alendronates for the prevention of symptomatic vertebral fracture in elderly GIOP patients (more than 65 years old) with collagen vascular diseases who have done teriparatide therapy
Safety,Efficacy
Confirmatory
Pragmatic
Phase IV
Symptomatic vertebral fractures, those are determined by conventional thoracic and spinal radiographs in lateral and antero-posterior projections at any time during 3 years of this study.
Non symptomatic vertebral fractures and non-vertebral fractures deetermined by plain X-ray.
Bone mineral density values, those are measured at the lumbar spine.
The serum levels of NTX, osteocalcin, 25(OH)vitamin D, etc.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
NO
No need to know
2
Treatment
Medicine |
Denosumab
alendronate
65 | years-old | <= |
Not applicable |
Male and Female
Patients with GIOP who have done full teriparatide therapy
1)Patients who have serious renal disorder (eGFR<35ml/min or Cr>1.5mg/ml)
2)Patient who has a history of renal stone past 5 years
3)Patients with primary or secondary hyperparathyroidism
4)Patients with hyperthyroidism or hypothyroidism
5)Patients who are considered to be contraindicated for bisphosphonates or denosumab
6)Patients who are treated with warfarin or digitalis
7)Patients who have newly received drugs having influence on bone remodeling within 6 months at inclusion of the study (estriol, estradiol, Vitamin D3, Vitamin K2, SERM(Raloxifene, bazedoxifene), Calcitonin, Ipriflavone, Steroids)
8)Patients who had received bisphosphonates during teriparatide therapy
9) Patients who are thought to be inappropriate for this study by physician
40
1st name | |
Middle name | |
Last name | Koichi Amano |
Saitama Medical Center,
Saitama Medical University
Department of Rheumatology and Clinical Immunology
1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan
0492283859
amanokoi@saitama-med.ac.jp
1st name | |
Middle name | |
Last name | Hirofumi Takei |
Saitama Medical Center, Saitama Medical Universitity
Department of Rheumatology & Clinical Immunology
1981 Kamoda Kawagoe, Saitama 350-8550
0492283574
takeix@saitama-med.ac.jp
Saitama Medical University
Saitama Medical Center,
Saitama Medical University
Self funding
NO
2014 | Year | 07 | Month | 16 | Day |
Unpublished
Enrolling by invitation
2014 | Year | 07 | Month | 15 | Day |
2014 | Year | 09 | Month | 05 | Day |
2019 | Year | 12 | Month | 31 | Day |
2020 | Year | 03 | Month | 31 | Day |
2020 | Year | 06 | Month | 30 | Day |
2020 | Year | 12 | Month | 31 | Day |
2014 | Year | 07 | Month | 16 | Day |
2018 | Year | 08 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016947
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |